Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
41 hedge funds and large institutions have $118M invested in Genocea Biosciences, Inc. in 2014 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 5 closing their positions.
200% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 5
63% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 8
32% more funds holding
Funds holding: 31 → 41 (+10)
10% more capital invested
Capital invested by funds: $108M → $118M (+$10.4M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.6M |
| 2 |
SGAM
Steinberg Global Asset Management
Boca Raton,
Florida
|
+$301K |
| 3 |
Bank of New York Mellon
New York
|
+$257K |
| 4 |
BPC
Banque Pictet & Cie
Geneva 73,
Switzerland
|
+$220K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$215K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$3.64M |
| 2 |
DM
Deerfield Management
New York
|
-$3.35M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$2.28M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.46M |
| 5 |
Goldman Sachs
New York
|
-$344K |
GNCA Hedge Fund Activity: Q2 2014 in Review
41 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q2 2014, worth a combined $118M — up 9.7% from $108M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new GNCA positions and 5 closed out — a net gain of 10 holders — while 13 added to existing stakes and 8 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $17.6M. The largest seller was Jennison Associates, exiting entirely with an estimated $3.64M sold.
- 41 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q2 2014, up from 31 in Q1 2014.
- Funds reported $118M of Genocea Biosciences, Inc. stock for Q2 2014, up 9.7% quarter-over-quarter.
- 15 funds opened new Genocea Biosciences, Inc. positions in Q2 2014 and 5 closed out, a net change of +10 holders.
- The largest Genocea Biosciences, Inc. buyer in Q2 2014 was Fidelity Investments, an estimated $17.6M added.
- The largest Genocea Biosciences, Inc. seller in Q2 2014 was Jennison Associates, an estimated $3.64M sold.
Based on aggregated 13F filings for Q2 2014.